SG10201501733QA - Novel anti-cd38 antibodies for the treatment of cancer - Google Patents

Novel anti-cd38 antibodies for the treatment of cancer

Info

Publication number
SG10201501733QA
SG10201501733QA SG10201501733QA SG10201501733QA SG10201501733QA SG 10201501733Q A SG10201501733Q A SG 10201501733QA SG 10201501733Q A SG10201501733Q A SG 10201501733QA SG 10201501733Q A SG10201501733Q A SG 10201501733QA SG 10201501733Q A SG10201501733Q A SG 10201501733QA
Authority
SG
Singapore
Prior art keywords
antibodies
cancer
treatment
novel anti
novel
Prior art date
Application number
SG10201501733QA
Inventor
Peter U Park
Laura M Bartle
Anna Skaletskaya
Victor S Golmakher
Daniel Tavares
Jutta Deckert
Vincent Mikol
Veronique Blanc
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201501733Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of SG10201501733QA publication Critical patent/SG10201501733QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
SG10201501733QA 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer SG10201501733QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291628A EP1914242A1 (en) 2006-10-19 2006-10-19 Novel anti-CD38 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG10201501733QA true SG10201501733QA (en) 2015-04-29

Family

ID=37831721

Family Applications (4)

Application Number Title Priority Date Filing Date
SG2011064136A SG174777A1 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer
SG10201501733QA SG10201501733QA (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer
SG10202012950TA SG10202012950TA (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer
SG2011048956A SG173345A1 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011064136A SG174777A1 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202012950TA SG10202012950TA (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer
SG2011048956A SG173345A1 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer

Country Status (43)

Country Link
US (5) US8153765B2 (en)
EP (4) EP1914242A1 (en)
JP (2) JP5607364B2 (en)
KR (5) KR101852317B1 (en)
CN (1) CN101616933B (en)
AR (1) AR063488A1 (en)
AU (1) AU2007311511C1 (en)
BR (1) BRPI0718130B1 (en)
CA (2) CA2989609A1 (en)
CL (3) CL2007002995A1 (en)
CO (1) CO6190555A2 (en)
CR (1) CR10679A (en)
CY (2) CY1122302T1 (en)
DK (1) DK2076540T3 (en)
DO (1) DOP2017000177A (en)
EA (1) EA025215B1 (en)
ES (1) ES2726754T3 (en)
GT (1) GT200900079A (en)
HK (1) HK1139956A1 (en)
HR (1) HRP20190742T1 (en)
HU (2) HUE043351T2 (en)
IL (1) IL197217B (en)
LT (2) LT2076540T (en)
MA (1) MA30895B1 (en)
ME (1) MEP10609A (en)
MX (1) MX2009004050A (en)
MY (1) MY159374A (en)
NL (1) NL301077I2 (en)
NO (3) NO345911B1 (en)
NZ (1) NZ575188A (en)
PE (1) PE20081171A1 (en)
PL (1) PL2076540T3 (en)
PT (1) PT2076540T (en)
RS (1) RS58716B1 (en)
SG (4) SG174777A1 (en)
SI (1) SI2076540T1 (en)
SV (1) SV2009003203A (en)
TN (1) TN2009000058A1 (en)
TW (4) TWI538917B (en)
UA (1) UA114879C2 (en)
UY (1) UY30655A1 (en)
WO (1) WO2008047242A2 (en)
ZA (1) ZA200901395B (en)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
WO2006122355A1 (en) * 2005-05-16 2006-11-23 Qrsciences Pty Ltd A system and method for improving the analysis of chemical substances using nqr
CA2621982C (en) 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
EP1945671A2 (en) 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
ES2435779T3 (en) 2007-07-19 2013-12-23 Sanofi Cytotoxic agents comprising new tomaimycin derivatives and their therapeutic use
PA8849001A1 (en) * 2008-11-21 2010-06-28 Lilly Co Eli C-MET ANTIBODIES
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
FR2947269B1 (en) 2009-06-29 2013-01-18 Sanofi Aventis NEW ANTICANCER COMPOUNDS
FR2949469A1 (en) 2009-08-25 2011-03-04 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
UY32913A (en) 2009-10-02 2011-04-29 Sanofi Aventis NEW MAITANSINOIDS AND THE USE OF SUCH MAITANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY
MA33892B1 (en) 2009-12-22 2013-01-02 Roche Glycart Ag Antibodies against her3 and used
HUE027713T2 (en) * 2009-12-23 2016-10-28 Hoffmann La Roche Anti-bv8 antibodies and uses thereof
US9220743B2 (en) * 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
JP6093696B2 (en) 2010-06-09 2017-03-08 ゲンマブ エー／エス Antibody against human CD38
FR2963007B1 (en) 2010-07-26 2013-04-05 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ES2617446T3 (en) 2010-09-27 2017-06-19 Morphosys Ag Anti-cd38 and lenalidomide or bortezomib antibody for the treatment of multiple myeloma and nhl
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
AU2012204467B2 (en) * 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
KR102272828B1 (en) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 Preparation of maytansinoid antibody conjugates by a one-step process
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
RU2610336C2 (en) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. New conjugates binding compound - active compound (adc) and use thereof
EP3508500A1 (en) * 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR101860174B1 (en) 2011-09-20 2018-05-21 메디뮨 리미티드 Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CN110183470A (en) 2011-10-14 2019-08-30 麦迪穆有限责任公司 Pyrrolobenzodiazepines are tall and erect
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
BR112014009055B1 (en) 2011-10-14 2021-12-14 Seattle Genetics, Inc. PYRROLOBENZODIAZEPINE COMPOUNDS, TARGET CONJUGATES, DRUG BINDING AND USE OF SAID CONJUGATES TO TREAT A PROLIFERATIVE DISEASE
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013075740A1 (en) * 2011-11-23 2013-05-30 Sanofi Antibody purification method
EP2812702B1 (en) * 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
SG11201500087VA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti-cd22 antibodies
JP2015523380A (en) 2012-07-09 2015-08-13 ジェネンテック， インコーポレイテッド Immune complex comprising anti-CD79B antibody
BR112015002193A2 (en) 2012-08-02 2017-07-04 Genentech Inc anti-etbr and immunoconjugate antibodies
PT2900232T (en) 2012-09-25 2018-02-09 Morphosys Ag Combinations and uses thereof
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
PL2906253T3 (en) 2012-10-12 2019-02-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
MX364329B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates.
CA2885315C (en) 2012-10-12 2020-06-23 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
KR101819404B1 (en) 2012-10-12 2018-02-28 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
CN105102068B (en) 2012-10-12 2018-06-01 Adc疗法责任有限公司 Pyrrolobenzodiazepines Zhuo-antibody conjugates
WO2014057072A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
WO2014068114A1 (en) 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
TWI609887B (en) 2012-11-05 2018-01-01 皮爾法伯製藥公司 Novel antigen binding proteins and their use as addressing product for the treatment of cancer
UA118255C2 (en) * 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
IL241407B (en) * 2013-03-13 2022-06-01 Univ California Compositions comprising anti-cd38 antibodies and carfilzomib
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
BR112015023070B1 (en) 2013-03-13 2022-06-07 Genentech, Inc. Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition comprising the same, as well as their uses for the treatment of a proliferative disease
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP6436965B2 (en) 2013-03-14 2018-12-12 ジェネンテック， インコーポレイテッド Anti-B7-H4 antibody and immunoconjugate
PT2992013T (en) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
HUE038741T2 (en) * 2013-05-06 2018-11-28 Sanofi Sa Continuous multistep process for purifying antibodies
BR112016002829A2 (en) 2013-08-12 2017-09-19 Genentech Inc COMPOUND AND PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION, CANCER TREATMENT METHOD, CANCER TREATMENT KIT, DRUG LINKER INTERMEDIATE, CBI DIMER DRUG MOUNT AND COMPOUND
CN105518027A (en) 2013-09-17 2016-04-20 豪夫迈·罗氏有限公司 Methods of using anti-LGR5 antibodies
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CN103513040B (en) * 2013-10-16 2015-03-11 常晓天 Application of protein CD38 to preparation of rheumatoid arthritis diagnosing marker
JP2016536314A (en) * 2013-10-31 2016-11-24 サノフイ Specific anti-CD38 antibodies for treating human cancer
SG11201603244VA (en) 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
PE20160712A1 (en) 2013-12-13 2016-07-26 Genentech Inc ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES
KR20160092024A (en) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
JP2017506640A (en) * 2014-02-14 2017-03-09 セントローズ， エルエルシー Extracellular targeted drug conjugates
JP6673838B2 (en) 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ Immunotherapy cells engineered to target antigens present on both immune and diseased cells
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
BR112016022385A2 (en) * 2014-03-28 2018-06-19 Xencor, Inc specific antibodies that bind to cd38 and cd3
UA119352C2 (en) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
CN106414499A (en) 2014-05-22 2017-02-15 基因泰克公司 Anti-GPC3 antibodies and immunoconjugates
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
EP3154581B1 (en) 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
KR20170032406A (en) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 Engineered cells for adoptive cell therapy
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
WO2016040294A2 (en) * 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PT3191135T (en) 2014-09-12 2020-11-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AR101846A1 (en) 2014-09-12 2017-01-18 Genentech Inc ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
CN113929782B (en) * 2014-09-16 2024-06-21 依奈特制药公司 Neutralization of inhibitory pathways in lymphocytes
JP6730261B2 (en) 2014-09-17 2020-07-29 ジェネンテック， インコーポレイテッド Immune complex containing anti-HER2 antibody
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (en) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES
SG11201703599VA (en) 2014-11-19 2017-06-29 Immunogen Inc Process for preparing cell-binding agent-cytotoxic agent conjugates
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
CN110894240B (en) 2014-11-26 2022-04-15 森科股份有限公司 Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
NZ732753A (en) * 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
HUE054271T2 (en) 2015-05-13 2021-08-30 Morphosys Ag Treatment for multiple myeloma (mm)
KR102602754B1 (en) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
US9644032B2 (en) 2015-05-29 2017-05-09 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
ES2890783T3 (en) 2015-06-22 2022-01-24 Janssen Biotech Inc Combination therapies for hematologic malignancies with anti-CD38 antibodies and survivin inhibitors
JP6971858B2 (en) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzyme-cleaving groups
FI3313441T3 (en) 2015-06-24 2024-03-28 Janssen Biotech Inc Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
CA2998611A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (en) 2015-11-03 2018-08-31 詹森生物科技公司 The subcutaneous preparations and application thereof of 8 antibody of AntiCD3 McAb
CN105837688B (en) * 2015-11-20 2019-02-26 北京大学深圳研究生院 Single domain antibody and its encoding gene, immunotoxin and its encoding gene, preparation method, expression vector, application and host cell
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CN113817060B (en) * 2016-01-09 2024-03-08 嘉立医疗科技(广州)有限公司 Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3016098A1 (en) 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
MX2018011627A (en) 2016-03-24 2019-01-10 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups.
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR20200087875A (en) 2016-04-15 2020-07-21 바이오아트라, 엘엘씨 Anti-axl antibodies and their immunoconjugates and uses thereof
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
US11254742B2 (en) 2016-05-13 2022-02-22 Bioatla, Inc. Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CN109310781B (en) 2016-06-15 2024-06-18 拜耳制药股份公司 Specific antibody-drug-conjugates (ADC) having a KSP inhibitor and an anti-CD 123-antibody
US20190233533A1 (en) * 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3484923A1 (en) * 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN117717604A (en) 2016-07-19 2024-03-19 梯瓦制药澳大利亚股份有限公司 anti-CD 47 combination therapy
EP3487506A1 (en) 2016-07-20 2019-05-29 Hybrigenics SA Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP2019526579A (en) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Methods and compositions for targeting T cell cancer
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CN109890422A (en) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 Taxol-albumin-binding agent composition and the method for using and preparing the composition
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TWI788307B (en) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP7066714B2 (en) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト Antibody drug conjugate (ADC) with an enzymatically cleavable group
EP3558387B1 (en) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
CN109963570A (en) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 Application of-the O- of the Paeoniflorin -6 ' benzene sulfonate in treatment Sjogren syndrome
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PL3544636T3 (en) 2017-02-08 2021-12-06 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (en) 2017-04-18 2022-09-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
WO2018234370A1 (en) 2017-06-20 2018-12-27 Institut Curie Immune cells defective for suv39h1
US11191845B2 (en) 2017-06-20 2021-12-07 Sorrento Therapeutics, Inc. CD38 antibody drug conjugate
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
BR112020002636A2 (en) * 2017-08-10 2020-07-28 Grifols Diagnostic Solutions Inc. compositions, methods and / or kits comprising a recombinant extracellular domain of human cd38
AU2018316521A1 (en) * 2017-08-16 2020-02-13 Black Belt Therapeutics Limited CD38 modulating antibody
SG11202000484TA (en) * 2017-08-16 2020-02-27 Black Belt Therapeutics Ltd Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2019055689A1 (en) 2017-09-13 2019-03-21 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
JP2020533380A (en) * 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Combination treatment of cancer
KR20200061376A (en) 2017-09-29 2020-06-02 다이이찌 산쿄 가부시키가이샤 Antibody-pyrrolobenzodiazepine derivative conjugate
WO2019070726A1 (en) * 2017-10-02 2019-04-11 Visterra, Inc. Antibody molecules to cd138 and uses thereof
MX2020004129A (en) * 2017-10-10 2020-08-20 Sanofi Sa Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies.
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN111542596A (en) 2017-11-01 2020-08-14 朱诺治疗学股份有限公司 Methods of producing therapeutic compositions of engineered cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MX2020004239A (en) 2017-11-01 2020-09-09 Juno Therapeutics Inc Process for producing a t cell composition.
TW201932482A (en) 2017-11-01 2019-08-16 美商奇諾治療有限公司 Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
EP3706785A4 (en) * 2017-11-10 2021-08-04 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
MX2020005907A (en) 2017-12-08 2020-10-19 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof.
JP2021505168A (en) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド Methods for Producing Manipulated T Cell Compositions
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
WO2019149743A1 (en) 2018-01-30 2019-08-08 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN110144008B (en) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 CD38 protein antibody and application thereof
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
EP3762031A4 (en) * 2018-03-08 2021-12-22 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
BR112020023187A2 (en) 2018-05-16 2021-04-20 Janssen Biotech, Inc. methods for treating cancers and increasing the effectiveness of therapeutic t-cell redirecting agents
CN108752475B (en) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 Anti-human CD38 antibodies and uses thereof
TW202019962A (en) 2018-07-10 2020-06-01 法商賽諾菲公司 Combination therapies targeting cd38 and tgf-beta
US11939377B2 (en) 2018-07-12 2024-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
TW202019518A (en) 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Variants of cd38 antibody and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
SG11202101130VA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Methods for assessing integrated nucleic acids
AU2019338999A1 (en) * 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
CN109265551B (en) * 2018-09-25 2020-09-15 华东师范大学 CD38 antibodies, chimeric antigen receptors, and drugs
CN109293773B (en) * 2018-09-25 2020-09-04 上海邦耀生物科技有限公司 Antibodies, chimeric antigen receptors and drugs targeting CD38 protein
EP3867275A2 (en) 2018-10-17 2021-08-25 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
US20210388106A1 (en) 2018-10-26 2021-12-16 Teneobio, Inc. Heavy chain antibodies binding to cd38
SG11202103873VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
MA54248A (en) 2018-11-13 2021-09-22 Janssen Biotech Inc REGULATION OF TRACE METALS DURING ANTI-CD38 ANTIBODY PRODUCTION
WO2020120730A1 (en) * 2018-12-14 2020-06-18 Morphosys Ag Antibody formulations
CN113490510A (en) 2019-01-08 2021-10-08 美国政府(由卫生和人类服务部的部长所代表) Cross-species single domain antibodies targeting mesothelin for the treatment of solid tumors
AU2020212534A1 (en) 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN113474362B (en) * 2019-01-28 2023-04-18 普众发现医药科技(上海)有限公司 Antibodies specific for CD44
MA54860A (en) 2019-01-28 2022-05-04 Sanofi Sa MULTIPLE MYELOMA TREATMENT METHODS
CA3130695A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
KR20220002891A (en) 2019-03-15 2022-01-07 모르포시스 아게 Anti-CD38 antibody and pharmaceutical composition thereof for treatment of autoantibody-mediated autoimmune disease
TW202104269A (en) * 2019-04-23 2021-02-01 法商賽諾菲公司 Anti-cd38 antibodies and formulations
SG11202111360YA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021021200A2 (en) 2019-05-01 2021-12-21 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides, and methods
BR112021022503A2 (en) 2019-05-14 2021-12-28 Sanofi Sa Anti-cd38 Antibody Administration Methods to Treat Multiple Myeloma
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
MX2021015433A (en) 2019-07-02 2022-06-08 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements.
AU2020318781A1 (en) 2019-07-23 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SUV39H1
CA3155246A1 (en) * 2019-10-21 2021-04-29 Sandro MATOSEVIC Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
JP2022552875A (en) 2019-10-22 2022-12-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ High-affinity Nanobodies Targeting B7H3 (CD276) for Treating Various Solid Tumors
WO2021092171A1 (en) 2019-11-06 2021-05-14 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
CN112876563B (en) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 Pharmaceutical composition, preparation method and application thereof
US20210188996A1 (en) 2019-12-05 2021-06-24 Sanofi-Aventis U.S. Llc Formulations of anti-cd38 antibodies for subcutaneous administration
EP4069740A1 (en) * 2019-12-06 2022-10-12 Sanofi-Aventis U.S. LLC Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma
CA3161573A1 (en) 2019-12-12 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
JP2023507120A (en) 2019-12-18 2023-02-21 テネオフォー， インコーポレイテッド A heavy chain antibody that binds to CD38
WO2021144457A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
KR20230005268A (en) * 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 Anti-CD19 Antibodies and Uses Thereof
CN115803824A (en) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 Methods of identifying characteristics associated with clinical response and uses thereof
CN116234558A (en) 2020-06-26 2023-06-06 朱诺治疗学有限公司 Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CN111808193B (en) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 Nanobody capable of binding human CD38 and application thereof
KR20230074713A (en) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Immune cells defective in SOCS1
CN114075285B (en) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 Humanized monoclonal antibody against human CD38 and application thereof
EP4211244A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Compositions and methods for cd38 modification
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN112300281B (en) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 Pharmaceutical composition containing NK cells and use thereof for treating cancer
US20220135696A1 (en) 2020-11-03 2022-05-05 Sanofi-Aventis U.S. Llc Use of isatuximab for the treatment of multiple myeloma
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
EP4251282A1 (en) 2020-11-27 2023-10-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for diagnosis and monitoring of toxic epidermal necrolysis
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
US20220202859A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
JP2024509853A (en) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Combination of T cell therapy and DGK inhibitor
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
TW202309077A (en) 2021-05-12 2023-03-01 瑞士商Ｃｒｉｓｐｒ治療公司 Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
CN113244175B (en) * 2021-05-22 2022-11-04 苏州大学 Immune vesicle maytansine conjugate as well as preparation method and application thereof
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
CN117500831A (en) 2021-06-09 2024-02-02 美国政府(由卫生和人类服务部的部长所代表) Cross-species single domain antibodies targeting PD-L1 for the treatment of solid tumors
CN113278075B (en) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 Inflammation detection kit
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TW202321303A (en) 2021-07-19 2023-06-01 德商莫菲西斯公司 Treatment of anti-pla2r-autoantibody-mediated membranous nephropathy
MX2024001211A (en) 2021-07-28 2024-02-12 Genentech Inc Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers.
TW202321308A (en) 2021-09-30 2023-06-01 美商建南德克公司 Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN113896802A (en) * 2021-10-09 2022-01-07 宜明昂科生物医药技术（上海）有限公司 Recombinant fusion protein targeting CD47 and CD38, and preparation and application thereof
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
CA3237175A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
CN113912727B (en) * 2021-11-16 2023-05-02 福州迈新生物技术开发有限公司 anti-CD 38 protein monoclonal antibody, cell line, preparation method and application thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
CN114457017B (en) * 2022-01-19 2023-10-17 四川大学华西第二医院 Mouse fibroblast tumor cell strain HXLyAF-KBM and application thereof
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023159182A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
AU2023231217A1 (en) 2022-03-07 2024-10-17 Marielle CHIRON BLONDEL Use of isatuximab in combination with other agents for the treatment of multiple myeloma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024040151A1 (en) 2022-08-18 2024-02-22 Pfizer Inc. Sirp alpha fusion protein and anti-cd38 antibody combination therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
TW202423970A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and cd38 antibodies
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024095173A1 (en) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Methods of treating cancers
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
US2429004A (en) 1947-02-20 1947-10-14 Wachsman Michael Fabric contacting circuit closer for knitting machines
FR1516743A (en) 1966-04-01 1968-02-05 Rhone Poulenc Sa New antibiotic and its method of preparation by culture of streptomyces croceus
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (en) 1988-04-16 1995-06-01 Celltech Ltd PROCEDURE FOR PRODUCING PROTEINS BY RECOMBINANT DNA.
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
ES2315612T3 (en) 1991-04-10 2009-04-01 The Scripps Research Institute GENOTECAS OF HETERODYMERIC RECEPTORS USING PHAGEMIDS.
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
JPH06511156A (en) * 1992-07-16 1994-12-15 イコス　コーポレイション Relief of symptoms associated with inflammatory disease conditions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH09506262A (en) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション Method for producing specific antibody
ES2247204T3 (en) 1994-01-31 2006-03-01 Trustees Of Boston University BANKS OF POLYCLONAL ANTIBODIES.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (en) 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
AU757510C (en) 1998-08-27 2003-09-11 Medimmune Limited Pyrrolobenzodiazepines
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
ATE349438T1 (en) 1999-11-24 2007-01-15 Immunogen Inc CYTOTOXIC ACTIVE INGREDIENTS CONTAINING TAXANES AND THEIR THERAPEUTIC USE
DE60031793T2 (en) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge DOXORUBICIN AND DAUNORUBICIN-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE
JP2003534022A (en) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Anti-RANK ligand monoclonal antibodies useful for treating RANK ligand mediated disorders
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EA013224B1 (en) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Cells producing antibody compositions
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
AU2003295411A1 (en) * 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
CA2504818C (en) 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
US20050208627A1 (en) * 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
AU2004280066A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
ATE516288T1 (en) 2003-10-22 2011-07-15 Us Gov Health & Human Serv PYRROLOBENZODIAZEPINE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND RELATED METHODS
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
ES2541489T3 (en) * 2004-02-06 2015-07-21 Morphosys Ag Human anti-CD38 antibodies and uses for them
EP1723152B1 (en) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
EP2360186B1 (en) * 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
JP2008504029A (en) * 2004-06-21 2008-02-14 ワシントン・ユニバーシティ Antibodies against West Nile virus and their therapeutic and prophylactic use
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US7732131B2 (en) * 2004-08-03 2010-06-08 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006066171A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
AU2006214121B9 (en) * 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
CN107033243B (en) * 2005-03-23 2020-12-15 根马布股份公司 CD38 antibodies for the treatment of multiple myeloma
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20090123950A1 (en) * 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
DE102005030112A1 (en) 2005-06-28 2007-01-18 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH filler alloy
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
ATE527262T1 (en) 2006-01-25 2011-10-15 Sanofi Sa NEW CYTOTOXIC AGENTS CONTAINING TOMAYMYCIN DERIVATIVES
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
NZ590330A (en) 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
ES2617446T3 (en) * 2010-09-27 2017-06-19 Morphosys Ag Anti-cd38 and lenalidomide or bortezomib antibody for the treatment of multiple myeloma and nhl
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
SG11201401518TA (en) * 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013125861A1 (en) 2012-02-20 2013-08-29 주식회사 노리코리아 Method and system for providing education service based on knowledge unit, and computer-readable recording medium
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
WO2016040294A2 (en) * 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
NZ732753A (en) * 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
WO2016111677A1 (en) * 2015-01-06 2016-07-14 Hewlett-Packard Development Company, L.P. Adapter to concatenate connectors
KR102602754B1 (en) * 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
ES2890783T3 (en) * 2015-06-22 2022-01-24 Janssen Biotech Inc Combination therapies for hematologic malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN108472369A (en) * 2015-11-03 2018-08-31 詹森生物科技公司 The subcutaneous preparations and application thereof of 8 antibody of AntiCD3 McAb
US10781261B2 (en) * 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MX2020004129A (en) * 2017-10-10 2020-08-20 Sanofi Sa Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies.
US11605302B2 (en) 2020-11-10 2023-03-14 Rockwell Collins, Inc. Time-critical obstacle avoidance path planning in uncertain environments

Also Published As

Publication number Publication date
IL197217B (en) 2019-12-31
CA2989609A1 (en) 2008-04-24
TWI609884B (en) 2018-01-01
TN2009000058A1 (en) 2010-08-19
AU2007311511B9 (en) 2020-11-12
ZA200901395B (en) 2010-06-30
KR20150119976A (en) 2015-10-26
CN101616933B (en) 2015-06-10
ME00614B (en) 2011-12-20
EP2076540A2 (en) 2009-07-08
CA2663209A1 (en) 2008-04-24
CA2663209C (en) 2018-02-13
CY2020039I1 (en) 2021-03-12
CY2020039I2 (en) 2021-05-05
TWI609885B (en) 2018-01-01
KR101800328B1 (en) 2017-11-22
MX2009004050A (en) 2009-04-28
NO345911B1 (en) 2021-10-11
SG10202012950TA (en) 2021-02-25
HK1139956A1 (en) 2010-09-30
TW201630938A (en) 2016-09-01
CN101616933A (en) 2009-12-30
MY159374A (en) 2016-12-30
US20110262454A1 (en) 2011-10-27
KR101852317B1 (en) 2018-04-25
HUE043351T2 (en) 2019-08-28
NO20211026A1 (en) 2009-05-13
MEP10609A (en) 2011-12-20
JP2014221761A (en) 2014-11-27
NL301077I1 (en) 2020-12-02
MA30895B1 (en) 2009-11-02
SG173345A1 (en) 2011-08-29
GT200900079A (en) 2010-07-09
CO6190555A2 (en) 2010-08-19
JP5607364B2 (en) 2014-10-15
US8153765B2 (en) 2012-04-10
NO2021044I1 (en) 2021-10-13
ES2726754T3 (en) 2019-10-09
CR10679A (en) 2009-06-24
US20090304710A1 (en) 2009-12-10
WO2008047242A9 (en) 2009-02-05
JP2010506582A (en) 2010-03-04
KR20090078330A (en) 2009-07-17
EP3909980A1 (en) 2021-11-17
AU2007311511C1 (en) 2021-11-04
TW201518322A (en) 2015-05-16
CL2007002995A1 (en) 2008-05-16
NL301077I2 (en) 2021-02-03
AU2007311511B2 (en) 2013-08-22
RS58716B1 (en) 2019-06-28
PL2076540T3 (en) 2019-08-30
NZ575188A (en) 2012-07-27
TW201734053A (en) 2017-10-01
WO2008047242A3 (en) 2008-06-26
WO2008047242A8 (en) 2009-08-06
EP3498735A1 (en) 2019-06-19
BRPI0718130B1 (en) 2022-05-03
EA025215B1 (en) 2016-12-30
AR063488A1 (en) 2009-01-28
WO2008047242A2 (en) 2008-04-24
HUS2000048I1 (en) 2020-12-28
SG174777A1 (en) 2011-10-28
KR20170129960A (en) 2017-11-27
PT2076540T (en) 2019-06-06
HRP20190742T1 (en) 2019-06-14
UY30655A1 (en) 2008-05-31
CL2017001580A1 (en) 2018-03-02
EP1914242A1 (en) 2008-04-23
BRPI0718130A2 (en) 2013-11-05
LTPA2020536I1 (en) 2020-12-28
IL197217A0 (en) 2011-08-01
SI2076540T1 (en) 2019-06-28
US20120156218A1 (en) 2012-06-21
TW200823236A (en) 2008-06-01
KR101534452B1 (en) 2015-07-06
DK2076540T3 (en) 2019-05-13
KR20150023010A (en) 2015-03-04
NO20091712L (en) 2009-05-13
EA200970393A1 (en) 2009-12-30
AU2007311511A1 (en) 2008-04-24
KR20140105035A (en) 2014-08-29
EP2076540B1 (en) 2019-02-27
PE20081171A1 (en) 2008-09-26
JP6121366B2 (en) 2017-04-26
LT2076540T (en) 2019-06-10
SV2009003203A (en) 2009-10-27
TWI538917B (en) 2016-06-21
DOP2017000177A (en) 2017-09-15
US20200408765A1 (en) 2020-12-31
US20170343550A1 (en) 2017-11-30
CL2012002012A1 (en) 2012-11-05
CY1122302T1 (en) 2021-01-27
UA114879C2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
HUS2000048I1 (en) Novel anti-cd38 antibodies for the treatment of cancer
HRP20181565T1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
IL238668A0 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
IL197914A (en) Anti-ereg antibodies for treating cancer
HRP20180485T1 (en) Monoclonal antibodies for treatment of cancer
PT3199180T (en) Epha3 antibodies for the treatment of solid tumors
EP2029172A4 (en) Anti-c35 antibodies for treating cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0604114D0 (en) Combinations for the treatment of cancer